Effects of

Gentiana lutea Gentienacea family anti-atherogenic. anti-inflammatory antioxidant phytochemistry treatment of vascular diseases vascular diseases

Journal

Current vascular pharmacology
ISSN: 1875-6212
Titre abrégé: Curr Vasc Pharmacol
Pays: United Arab Emirates
ID NLM: 101157208

Informations de publication

Date de publication:
2021
Historique:
received: 03 02 2020
revised: 05 05 2020
accepted: 07 05 2020
pubmed: 30 5 2020
medline: 6 1 2022
entrez: 30 5 2020
Statut: ppublish

Résumé

Gentiana lutea (GL), commonly known as yellow gentian, bitter root, and bitterwort, belongs to family Gentianaceae. GL belongs to genus Gentiana, which is a rich natural source of iridoids, secoiridoids, xantones, flavonoids, triterpenoids, and carbohydrates. Medicinal plants from Gentiana species have anti-oxidant, anti-inflammatory, anti-mitogenic, anti-proliferative, and lipidlowering effects, as well as a cardioprotective, hypotensive, vasodilator and anti-platelet activities. We reviewed the recent literature related to the effects of Gentiana species, and their active components on vascular diseases. Data used for this review were obtained by searching the electronic database [PUBMED/ MEDLINE 1973 - February 2020]. The primary data search terms of interest were: Gentiana lutea, Gentienacea family, phytochemistry, vascular diseases, treatment of vascular diseases, antioxidant, anti-inflammatory, anti-atherogenic. Gentiana species and their constituents affect many different factors related to vascular disease development and progression. Therefore, Gentiana-based therapeutics represent potentially useful drugs for the management of vascular diseases.

Sections du résumé

BACKGROUND
Gentiana lutea (GL), commonly known as yellow gentian, bitter root, and bitterwort, belongs to family Gentianaceae. GL belongs to genus Gentiana, which is a rich natural source of iridoids, secoiridoids, xantones, flavonoids, triterpenoids, and carbohydrates. Medicinal plants from Gentiana species have anti-oxidant, anti-inflammatory, anti-mitogenic, anti-proliferative, and lipidlowering effects, as well as a cardioprotective, hypotensive, vasodilator and anti-platelet activities.
OBJECTIVE
We reviewed the recent literature related to the effects of Gentiana species, and their active components on vascular diseases.
METHODS
Data used for this review were obtained by searching the electronic database [PUBMED/ MEDLINE 1973 - February 2020]. The primary data search terms of interest were: Gentiana lutea, Gentienacea family, phytochemistry, vascular diseases, treatment of vascular diseases, antioxidant, anti-inflammatory, anti-atherogenic.
CONCLUSION
Gentiana species and their constituents affect many different factors related to vascular disease development and progression. Therefore, Gentiana-based therapeutics represent potentially useful drugs for the management of vascular diseases.

Identifiants

pubmed: 32469702
pii: CVP-EPUB-106972
doi: 10.2174/1570161118666200529111314
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

359-369

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Gordana Joksic (G)

"VINČA" Institute of Nuclear Sciences - National Institute of thе Republic of Serbia, University of Belgrade, Department of Physical Chemistry, Belgrade, Serbia.

Djordje Radak (D)

Serbian Academy of Sciences and Arts, Belgrade, Serbia.

Emina Sudar-Milovanovic (E)

"VINČA" Institute of Nuclear Sciences - National Institute of thе Republic of Serbia, University of Belgrade, Department of Radiobiology and Molecular Genetics, Belgrade, Serbia.

Milan Obradovic (M)

"VINČA" Institute of Nuclear Sciences - National Institute of thе Republic of Serbia, University of Belgrade, Department of Radiobiology and Molecular Genetics, Belgrade, Serbia.

Jelena Radovanovic (J)

"VINČA" Institute of Nuclear Sciences - National Institute of thе Republic of Serbia, University of Belgrade, Department of Radiobiology and Molecular Genetics, Belgrade, Serbia.

Esma R Isenovic (ER)

"VINČA" Institute of Nuclear Sciences - National Institute of thе Republic of Serbia, University of Belgrade, Department of Radiobiology and Molecular Genetics, Belgrade, Serbia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH